Gastrointestinal Drugs Global Market Report 2022 covers this critical market and the impact on it from the Covid 19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for gastrointestinal drugs. Vitamins and Minerals play a crucial role in the treatment of pateints with Covid 19 as they are used as immunity boosters.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider gastrointestinal drugs market, and compares it with other markets.
2) By Drug Type: Antacids; Antiulcerants; Antiobesity; Antiemetics And Antinauseants; Antidiarrhoeals
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
4) By Route Of Administration: Oral; Parenteral; Others
5) By Drug Classification: Branded Drugs; Generic Drugs
6) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Companies Mentioned: Takeda Pharmaceuticals; Bayer AG; Abbott Laboratories; Otsuka Holdings Co. ltd.; Johnson & Johnson
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, gastrointestinal drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 3-5 business days.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the gastrointestinal drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Gastrointestinal Drugs Market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider gastrointestinal drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The gastrointestinal drugs market section of the report gives context. It compares the gastrointestinal drugs market with other segments of the gastrointestinal drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, gastrointestinal drugs indicators comparison.
Scope
Markets Covered:
1) By Type: Pharmaceutical Drugs; Biologics2) By Drug Type: Antacids; Antiulcerants; Antiobesity; Antiemetics And Antinauseants; Antidiarrhoeals
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
4) By Route Of Administration: Oral; Parenteral; Others
5) By Drug Classification: Branded Drugs; Generic Drugs
6) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Companies Mentioned: Takeda Pharmaceuticals; Bayer AG; Abbott Laboratories; Otsuka Holdings Co. ltd.; Johnson & Johnson
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, gastrointestinal drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Report Structure7. Gastrointestinal Drugs Market Trends And Strategies8. Impact Of COVID-19 On Gastrointestinal Drugs21. Key Mergers And Acquisitions In The Gastrointestinal Drugs Market25. Copyright And Disclaimer
3. Gastrointestinal Drugs Market Characteristics
4. Gastrointestinal Drugs Market Product Analysis
5. Gastrointestinal Drugs Market Supply Chain
6. Gastrointestinal Drugs Market Customer Information
9. Gastrointestinal Drugs Market Size And Growth
10. Gastrointestinal Drugs Market Regional Analysis
11. Gastrointestinal Drugs Market Segmentation
12. Gastrointestinal Drugs Market Metrics
13. Asia-Pacific Gastrointestinal Drugs Market
14. Western Europe Gastrointestinal Drugs Market
15. Eastern Europe Gastrointestinal Drugs Market
16. North America Gastrointestinal Drugs Market
17. South America Gastrointestinal Drugs Market
18. Middle East Gastrointestinal Drugs Market
19. Africa Gastrointestinal Drugs Market
20. Gastrointestinal Drugs Market Competitive Landscape
22. Market Background: Pharmaceutical Drugs Market
23. Recommendations
24. Appendix
Executive Summary
Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co. ltd., Johnson & Johnson, Reckitt Benckiser Group plc., Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company.The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $86.96 billion in 2026 at a CAGR of 3.6%.
The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant.
The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The different types include pharmaceutical drugs, and biologics. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others.
North America was the largest region in the gastrointestinal drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.
During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value.
Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases.
The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Takeda Pharmaceuticals
- Bayer AG
- Abbott Laboratories
- Otsuka Holdings Co. ltd.
- Johnson & Johnson
- Reckitt Benckiser Group plc.
- Bausch Health Companies Inc.
- Sanofi S.A.
- Procter & Gamble
- Daiichi Sankyo Company
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 300 |
Published | March 2022 |
Forecast Period | 2022 - 2026 |
Estimated Market Value ( USD | $ 75.63 billion |
Forecasted Market Value ( USD | $ 86.96 billion |
Compound Annual Growth Rate | 3.6% |
Regions Covered | Global |